GeoVax Labs, Inc. New Stock Prediction
AI-powered sentiment analysis and prediction trends for GOVX, updated each market day.
GOVX AI Sentiment
AI sees no strong directional signal for GeoVax Labs, Inc. New stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Sector
Exchange
Market Cap
$2,579,349
Cap Tier
Employees
17
Headquarters
SMYRNA, GA
Listed Since
Feb. 1, 1995
Website
GOVX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GOVX Volatility
GeoVax Labs, Inc. New has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
